Close Menu

IPO

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics has filed again for an initial public offering in the US.

This article has been updated from a previous version to include background on previous IPOs in the RNAi/microRNA market.

Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.

NEW YORK (GenomeWeb News) – Atossa Genetics lowered the expected share price for its planned initial public offering to between $4 and $6 per share, it disclosed in an amended Form S-1 filed on Monday with the US Securities and Exchange Commission.

NEW YORK (GenomeWeb News) – Venture capital investing into the 'omics-related and molecular diagnostics space remains challenging and is unlikely to improve in the near-term, according to some VC fund managers.

NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year, said in its amended Form S-1 that it net loss for full-year 2011 reached $3.4 million.

This article has been updated to correct information on the firm's tests.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.